Coherus Biosciences | CHRS - 負債





負債 変化する 日付
AbbVie USD 67.5B 67.5B 2025-12
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Akebia Therapeutics USD 46.51M 7.82M 2025-03
ALKERMES USD 70M 1.6M 2025-12
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amarin USD 0 0 2025-03
Amgen USD 54.6B 17M 2025-12
Baxter International USD 9.78B 68M 2025-12
Biogen USD 6.56B 275.1M 2026-03
BioMarin Pharmaceutical USD 605.86M 1.62M 2025-12
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Coherus Biosciences USD 294.92M 1.25M 2025-03
Eli Lilly USD 42.5B 3.6M 2025-12
Fujifilm JPY 922.82B 236.91B 2025-09
Gilead Sciences USD 24.94B 5M 2025-12
Ironwood Pharmaceuticals USD 583.99M 14.83M 2024-12
Merck USD 49.34B 7.97B 2025-12
Myriad Genetics USD 59.3M 19.7M 2025-03
Pacira USD 367.66M 4.53M 2026-03
Perrigo USD 3.64B 7.2M 2025-09
Pfizer USD 63.96B 3.11B 2025-12
PTC Therapeutics USD 2.71B 2.42B 2025-12
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Teva Pharmaceutical Industries USD 17.09B 21M 2025-12
Vertex Pharmaceuticals USD 2.03B 195.7M 2025-12
Xencor USD 69.27M 1.34M 2025-09
Zoetis USD 7.27B 482M 2025-09